Potential Applications of Intracellular Antibodies (intrabodies) in Stem Cell Therapeutics

Boon Chin Heng,D.M. Kemeny,Hua Liu,Tong Cao
DOI: https://doi.org/10.1111/j.1582-4934.2005.tb00348.x
2005-01-01
Journal of Cellular and Molecular Medicine
Abstract:In recent years, there has been growing interest in the use of antibodies to target intracellular molecules [1, 2]. This has been given further impetus by the development of the single chain variable fragment (scFv) antibody format [3], which facilitated the engineering and expression of functional antibodies within the intracellular environment. The recombinant antibody expressed within the confines of the intracellular environment is commonly referred to as an intrabody. More recently, the intracellular single variable domain (IDab) format composed of only the variable region of the immunoglobulin heavy chain (VH), has been demonstrated to make successful intrabodies that display excellent solubility, stability and expression within the cells of higher organisms [4, 5]. Indeed, this could offer a more advantageous format for intrabody construction and isolation than scFv, since there is no longer a need for phage display libraries with this approach [4]. The first reported use of an intrabody against an intracellular target was in 1988, when heavy and light-chain cDNAs of an antibody that neutralized the yeast alcohol dehydrogenase I (ADH I) enzyme were expressed in Saccharomyces cerevisiae by Carlson and colleagues [6]. Since then, numerous studies have demonstrated the tremendous potential of intrabodies in various therapeutic applications [1, 2], particularly in cancer [7-9] and AIDS treatment [10-12]. At the same time, both embryonic and adult stem cells have aroused much interest over their potential applications in the newly emerging field of regenerative medicine. There are however numerous technical obstacles that have to be overcome, before widespread and routine application of stem cells in clinical therapy can materialize. Among the most formidable of these challenges include: 1) immunological barrier against allogenic transplantation of stem cells [13], 2) teratogenic potential of embryonic stem cells [14], 3) precise control of cell lineage determination [15], and 4) limited plasticity of adult stem cells [16]. The application of intrabody technology can potentially be used to overcome these various challenges faced in utilizing stem cells for clinical ther-
What problem does this paper attempt to address?